Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Di Perri

Showing results (151-160 of 177) with videos related to

Pageof 18
Sort By:
HIV Medicine|May 16, 2018
Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disordersM Trunfio, D Vai, C Montrucchio, et al.
Infection|December 3, 2011
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot studyS Bonora, A Calcagno, C Cometto, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infectionsI Motta, M Trunfio, A Calcagno, et al.
Journal of Neurovirology|January 19, 2022
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disordersA Barco, S Orlando, G Stroffolini, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2015
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)S Bonora, S Rusconi, A Calcagno, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2005
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical settingD González de Requena, S Bonora, S Garazzino, et al.
Infection|May 20, 2015
Ageing with HIV: a multidisciplinary reviewA Calcagno, S Nozza, C Muss, et al.
Infection|June 25, 2015
Erratum to: Ageing with HIV: a multidisciplinary reviewA Calcagno, S Nozza, C Mussi, et al.
Current HIV Research|August 10, 2014
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patientsS Bonora, A Calcagno, O Vigano, et al.
Antimicrobial Agents and Chemotherapy|February 6, 2013
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal functionA Calcagno, D Gonzalez de Requena, M Simiele, et al.
Pageof 18

Showing results (151-160 of 177) with videos related to

Sort By:
Pageof 18
HIV Medicine|May 16, 2018
Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disordersM Trunfio, D Vai, C Montrucchio, et al.
Infection|December 3, 2011
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot studyS Bonora, A Calcagno, C Cometto, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infectionsI Motta, M Trunfio, A Calcagno, et al.
Journal of Neurovirology|January 19, 2022
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disordersA Barco, S Orlando, G Stroffolini, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2015
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)S Bonora, S Rusconi, A Calcagno, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2005
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical settingD González de Requena, S Bonora, S Garazzino, et al.
Infection|May 20, 2015
Ageing with HIV: a multidisciplinary reviewA Calcagno, S Nozza, C Muss, et al.
Infection|June 25, 2015
Erratum to: Ageing with HIV: a multidisciplinary reviewA Calcagno, S Nozza, C Mussi, et al.
Current HIV Research|August 10, 2014
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patientsS Bonora, A Calcagno, O Vigano, et al.
Antimicrobial Agents and Chemotherapy|February 6, 2013
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal functionA Calcagno, D Gonzalez de Requena, M Simiele, et al.
Pageof 18